Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab)

May 17, 2018 – Ongoing ENCORE 601 biomarker analyses suggest enhanced clinical benefit in subpopulation of PD-(L)1 refractory NSCLC patients with high levels of peripheral blood monocytes; 29% ORR and 5.4 months PFS observed in subpopulation – – Potential registration